News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-positive-overall-survival-results-anktiva?field_nir_news_date_value[min]=

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-fda-approval-anktivar-first-class-il-15?field_nir_news_date_value[min]=

Commercial Readiness with ImmunityBio's Bobby Reddy, M.D. https://youtu.be/WtECko8gZIU?si=uDaArueGDs4WbEM7

https://www.investing.com/news/stock-market-news/immunitybio-shares-target-raised-by-piper-sandler-on-potential-approval-93CH-3351606

https://www.ntg24.de/Kann-ImmunityBio-die-hohen-Erwartungen-erfuellen-23032024-MF-Aktien

Jahresbericht 2023 https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=318172553&type=PDF&symbol=IBRX&cdn=296f596a69562a360e59733a44d0f1d4&companyName=ImmunityBio+Inc.&formType=10-K&formDescription=Annual+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2024-03-19

https://www.rttnews.com/corpinfo/fdadetail.aspx?id=2138

ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the target of a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 47,140,000 shares, a growth of 7.3% from the January 31st total of 43,930,000 shares. Currently, 36.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 4,150,000 shares, the days-to-cover ratio is currently 11.4 days.

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy https://ir.immunitybio.com/news-releases/news-release-details/niaid-sponsored-study-shows-n-803-combined-neutralizing?field_nir_news_date_value[min]=

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study https://ir.immunitybio.com/news-releases/news-release-details/n-803-combined-natural-killer-cells-showed-potential-reduce-hiv?field_nir_news_date_value[min]=

https://investorplace.com/2023/11/3-biotech-moonshots-to-bet-on-the-future-of-health/